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Abstract
Dopamine neurotransmission influences approach toward rewards and reward-related cues. The best cited interpretation of
this effect proposes that dopamine mediates the pleasure that commonly accompanies reward. This hypothesis has
received support in some animal models and a few studies in humans. However, direct assessments of the effect of
transiently increasing dopamine neurotransmission have been largely limited to the use of psychostimulant drugs, which
elevate brain levels of multiple neurotransmitters in addition to dopamine. In the present study we tested the effect of more
selectively elevating dopamine neurotransmission, as produced by administration of the immediate dopamine precursor, L-
DOPA (0, 100/25, 200/50 mg, Sinemet), in healthy human volunteers. Neither dose altered positive mood. The results
suggest that dopamine neurotransmission does not directly influence positive mood in humans.
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Introduction
Mesolimbic dopamine (DA) neurotransmission influences the
ability of rewards to elicit focused interest and approach [1–5].
One early and still frequently cited interpretation is that the
transmitter mediates pleasure [6]. This possibility was first
suggested following observations that neuroleptic medications
decreased amphetamine-induced subjective ‘‘high’’ in stimulant
drug abusers [7–9] and produced a sense of ‘‘psychic indifference’’
in patients with schizophrenia [10] while extended treatment with
high doses of L-DOPA led to hypomanic states in patients with
bipolar mood disorders [11]. Subsequently, a series of carefully
controlled and influential animal studies indicated that increases in
DA neurotransmission augmented instrumental responding for
electrical stimulation of the brain (ESB) [12] while decreased DA
neurotransmission disrupted responding for drugs, food, and ESB
[13–18]. The latter effects were not attributable to compromised
motor function since low doses of DA receptor antagonists
increased instrumental responding while higher doses produced
biphasic increases and decreases. These observations led to the
suggestion that DA receptor antagonists reduced the ability to
experience pleasure [6].
Some recent work is at least consistent with the anhedonia
hypothesis. For example, individual differences in the magnitude
of drug-induced striatal DA responses correlate with approach-
related personality traits [19–22] and the substance’s positive
subjective effects [23–31]. In the converse experiments, mood-
lowering effects of antipsychotic medications are predicted by their
extent of DA D2 receptor blockade [32–34].
Other work, though, has seemed inconsistent with a role of DA
in pleasure. First, in both humans [35,36] and in laboratory
animals [3,37] DA release in the ventral striatum can also be
evoked by aversive stimuli. Second, in operant conditioning
paradigms, DA release increases and then peaks just prior to a
lever press for reward and then gradually decreases thereafter
[38,39]. With experience DA comes to be released in response to
cues associated with the reward [38–40] but not when actually
receiving the reward [40,41]. Third, an extensive series of studies
has indicated that neither DA antagonists nor DA lesions alter
responses in the ‘taste reactivity’ paradigm, an animal model of
eating-related pleasure [2,42,43]. Finally, the majority of studies
have failed to replicate an ability of neuroleptic medications or
other DA lowering manipulations to decrease drug-induced
pleasure in humans [44–58].
Given the above controversies, the present study aimed to test
the effect of a more selective DA augmenter, L-DOPA, on mood
states in healthy human volunteers. Since individual differences in
approach-related traits predict differences in DA reactivity, it was
further hypothesized that those who scored higher on these traits
would exhibit greater mood elevation.
Results
There were no significant Group x Time interaction effects for
any of the POMS subscales (all ps.0.05, see Table 1), nor were
there significant main effects of personality (all ps.0.05). A three-
way Group x Personality subgroup x Time interaction raised the
possibility that NS2 predicted differential POMS Agreeable-
Hostile responses to L-DOPA, but this effect was no longer
significant when VAS ‘‘Nauseous’’ scores were entered as
covariates (F6, 114=0.804, p.0.05). Effects on nausea were mild
(peak change=1.4/10), and statistically significant for the 200 mg
L-DOPA dose only (F6, 126=2.839, p,0.05) (see Table 1).
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In the present study, the immediate DA precursor, L-DOPA,
did not affect positive subjective states in healthy human
volunteers, neither in the groups as a whole nor in subgroups
based on hypothesized DA-related personality traits. These
findings extend the results from previous drug challenge studies.
In contrast to non-specific DA augmenters, such as psychostim-
ulant drugs, which reliably and potently elevate mood in healthy
human volunteers [31,53,59–61], accumulating evidence indicates
that more selective DA receptor agonists do not (Table 2).
The inability to detect effects of L-DOPA on positive mood does
not preclude a relationship between DA neurotransmission,
personality traits and goal-directed behavior [11,19–22,62,63];
moreover, enhancements in goal-directed behavior may lead to
elevated mood [11,62–64]. However, the present results suggest
that drug-induced mood-elevating effects are more closely related
to neurotransmitters other than DA [3,37,62–69], perhaps
serotonin, norepinephrine, glutamate, GABA, endocannabinoids
and endogenous opioids [2,70–75].
If DA’s influence on reward seeking behaviors is not accounted
for by enhanced pleasure, this raises the question of why it has
these effects. Perhaps the best-supported alternative interpretation
from the animal literature proposes that DA enhances the
incentive salience of reward related cues, increasing their ability
to elicit focused interest and sustain effortful seeking [2,43,76].
This conclusion is largely based on extensive evidence that
decrements in DA neurotransmission reduce the willingness to
work for rewards [37,76] without changing responses in an index
of feeding related pleasure [2,43]. Accumulating work in humans
supports this interpretation also ([62], Table 2). For example, in a
series of studies conducted here, decreasing DA neurotransmission
disrupted the tendency of subjects to respond preferentially to
reward-related cues [55] and decreased the willingness to work for
abused drugs [53,58] and monetary reward [Cawley et al,
unpublished observations] on progressive ratio breakpoint sched-
ules; each of these effects was produced without reductions in
pleasure. Indeed, the majority of studies in humans have failed to
replicate an ability of various DA lowering manipulations to
diminish drug-induced pleasure [45–58].
The present results should be considered in light of the
following. First, there was no direct measure of the ability of L-
DOPA to increase DA, leaving open the possibility that mood
changes were not detected because L-DOPA failed to increase DA
levels. However, this seems unlikely since similar doses of L-DOPA
given to healthy human volunteers induce behavioural effects [77–
79] and increase striatal DA synthesis [80]. Pre-clinical studies
confirm that L-DOPA increases DA levels in the intact brains of
healthy animals, albeit to a lesser extent than in animal models of
Parkinson’s disease [81]. Although, to our knowledge, there are no
reports of L-DOPA induced DA release in healthy humans, the
administration of 250 mg more than doubles ventricular CSF
levels of the DA metabolite, DOPAC [82]. Moreover, robust L-
DOPA induced DA responses have been seen in patients with
Parkinson’s disease [83]; intriguingly, these effects are largest in
Table 1. Effect of L-DOPA on mood and nausea.
POMS Item Group Baseline T2 T3 T4 Peak Change
(+45 mins.) (+105 mins.) (+165 mins.)
Composed-Anxious Placebo 60.161.9 61.661.7 60.361.6 60.161.8 2 1.062.4
100 mg L-DOPA 57.462.6 58.962.3 57.762.4 58.162.2 0.1962.8
200 mg L-DOPA 56.762.0 58.662.0 55.862.1 57.362.2 0.6362.0
Elated-Depressed Placebo 54.761.4 54.261.4 58.161.7 55.161.6 2.161.7
100 mg L-DOPA 54.061.8 53.861.4 54.162.0 52.061.9 2 0.7561.2
200 mg L-DOPA 55.861.9 53.761.5 56.661.6 53.861.7 2 2.061.6
Energetic-Tired Placebo 51.661.4 49.461.6 56.161.8 53.361.4 0.6362.6
100 mg L-DOPA 55.162.0 51.062.1 53.662.4 52.062.5 2 5.062.2
200 mg L-DOPA 54.261.7 47.861.9 51.662.0 49.961.9 2 6.761.8
Agreeable-Hostile Placebo 55.661.8 54.761.9 56.361.9 53.861.4 2 2.361.8
100 mg L-DOPA 53.362.4 53.262.2 54.262.6 53.762.4 0.061.4
200 mg L-DOPA 52.161.5 50.661.7 51.461.6 50.161.9 2 2.561.6
Confident-Unsure Placebo 55.261.3 54.261.6 56.761.5 54.861.5 2 0.6961.2
100 mg L-DOPA 55.861.5 54.461.6 54.861.8 54.661.7 2 1.961.5
200 mg L-DOPA 53.661.7 52.261.8 53.062.1 52.961.7 2 0.7561.4
Clearheaded-Confused Placebo 57.061.7 55.461.6 58.461.6 56.461.6 2 1.362.4
100 mg L-DOPA 56.661.7 54.861.7 55.661.8 55.162.0 2 0.8162.3
200 mg L-DOPA 55.061.7 52.462.5 53.462.2 52.762.3 2 3.361.3
VAS Item
Nauseous Placebo 1.860.23 2.260.37 1.460.16 1.460.15 0.2560.47
100 mg L-DOPA 1.660.22 1.460.22 1.360.17 1.460.31 2 0.1360.36
200 mg L-DOPA 1.560.18 2.060.27 1.960.39 2.660.54
A, B, C 1.460.52
(Means6SEM).
A=significantly different from placebo, B=significantly different from baseline, p,0.05, C=significantly different from 100 mg L-DOPA group at T4.
doi:10.1371/journal.pone.0028370.t001
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dysregulation syndrome’’ [84,85]. Moreover, in these patients,
larger L-DOPA-induced DA responses are associated with higher
novelty- and fun-seeking personality traits, greater L-DOPA-
induced psychomotor activation, and greater drug ‘‘wanting’’ but
not drug ‘‘liking’’ [84]. Testing the effect of larger increases in DA
neurotransmission in healthy human volunteers will be difficult,
though, since higher doses of all currently available drugs that
selectively augment DA neurotransmission are limited by side
effects such as nausea, vomiting, dizziness and drowsiness. Indeed,
this limitation guided our selection of L-DOPA doses in the
present study. Second, we used a median split to determine the
high and low sub-groups for each of the approach-related
personality traits. It might be necessary to recruit participants
from the more extreme ends of the normative population
distribution for each of these traits in order to detect a differential
effect of a DAergic drug, since individual differences in DA
neurotransmission might be more pronounced in these more
extreme ends of the distribution. This noted, a post hoc examination
of our more extreme upper and lower quartiles also failed to
identify an effect on mood (all p-values$0.15). Finally, it is possible
that an effect on mood would have been seen with a larger sample
size. However, this is considered unlikely. The single largest effect
size was peak change to ‘Energetic-Tired’ scores (d=0.339), and
Table 2. The effect of dopamine-enhancing agents on positive mood states in healthy humans.
Drug Mechanism of Dose Study n Mood Effect on Details
Action Measures Positive Mood
Apomorphine Mixed D1/D2 10 mg/kg, s.c. [95] 9 VAS 0
agonist
Bromocriptine D2 agonist 1.25 mg, p.o. [96] 32 VAS NR VAS items corresponding to motivation and energy
2.5 mg, p.o. [97] 12 VAS 0
2.5 mg, p.o. [98] 21 VAS 0
1.25 mg, p.o. [99] 22 VAS 0
2.5 mg, p.o. [100] 40 AMS 0
1.25 mg, p.o. [101] 20 VAS Q Bromocriptine Q VAS Contented and q VAS Sad and
Antagonistic scores
1.25 mg, p.o. [102] 12 VAS 0
2.5 mg, p.o. [103] 16 AMS 0 Not clear what these scales measure
STAI
L-DOPA Selective DA 100 mg, p.o. [97] 12 VAS 0
augmenter 150 mg, p.o. [88] 14 VAS 0
200 mg, p.o. [104] 22 VAS NR Only measured VAS ‘‘Drowsiness’’
Lisuride D2 agonist 0.2 mg, p.o. [105] 12 VAS Q Adverse effects, such as nausea, vomiting and headache
No sedative effect
Pergolide Mixed D1/D2 0.1 mg, p.o. [106] 40 PANAS 0 Drugs administered daily for 5 days
agonist No acute drug effect (assessed on day 1)
0.1 mg, p.o. [100] 40 AMS 0
0.05 mg, p.o. [107] 15 VAS 0
0.1 mg, p.o. [103] 16 AMS Q Not clear what these scales measure
STAI
Pramipexole D2 agonist 0.5 mg, p.o. [97] 12 VAS 0
0.25 mg, p.o. [108] 10 POMS Q 0.5 mg Q euphoria and energy as measured by ARCI, Q
POMS
0.5 mg, p.o. ARCI vigor and positive mood and Q item ‘‘like drug’’ on DEQ
DEQ
0.5 mg, p.o. [109] 32 VAS 0
Tolcapone COMT 200 mg, p.o. [110] 25 POMS 0
inhibitor 200 mg, p.o. [111] 23 POMS 0
100 mg p.o. day 1 [112] 47 POMS 0
followed by 200
mg p.o. x 6 days
For the purpose of this table, measures of positive mood include the ARCI MBG subscale, POMS ‘‘Elated’’ subscale, and the VAS items ‘‘High,’’ ‘‘Rush,’’ ‘‘Euphoria,’’
‘‘Contentedness,’’ ‘‘Like Drug,’’ and ‘‘Good Effects.’’ Abbreviations: AMS, Adjective Mood Scale. ARCI, Addiction Research Center Inventory. NR, not reported. 0, No
change. PANAS, Positive and Negative Affect Scales. POMS, Profile of Mood States. VAS, visual analog scales. STAI, State Trait Anxiety Inventory.
doi:10.1371/journal.pone.0028370.t002
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require samples larger than 200. Following corrections for multiple
comparisons, these numbers increase further again.
In conclusion, L-DOPA failed to produce changes in positive
mood states in a group of healthy human volunteers. These
findings add to an accumulating literature suggesting that




The study was carried out in accordance with the Declaration of
Helsinki and was approved by the Research Ethics Board of the
McGill University Hospital Centre. All subjects gave informed
written consent.
Subjects
Fifty participants were recruited from the McGill University
campus through online classified advertisements. Forty-eight men
and women (29 females and 19 males; mean age 21.963.7 years)
completed the study. One participant was excluded due to
vomiting at the beginning of the test session and another was
excluded because of failure to comprehend the task instructions.
All were healthy, as determined by a physical exam, standard
laboratory tests, and an interview with the Structured Clinical
Interview for DSM-IV, axis I [86]. None had a personal history of
axis I psychiatric disorders. On the test day, all subjects tested
negative on a urine drug screen sensitive to cocaine, opiates,
phencyclidine, barbiturates, D
9-tetrahydrocannabinol, and am-
phetamines (Triage Panel for Drugs of Abuse, Biosite Diagnos-
tics, San Diego, CA).
Procedure
Participants completed the personality questionnaires on the
same day as the psychiatric interview, while the test session took
place on a separate day. Participants also completed a battery of
cognitive tasks during the test session, but these results will be
reported elsewhere. Participants were assigned to one of three
drug groups (n=16 per group): placebo, L-DOPA/carbidopa
(Sinemet, 100mg/25 mg) or L-DOPA/carbidopa (Sinemet,
200 mg/50 mg), in a randomized, double blind, between-groups
design. A combination drug, including the peripheral decarbox-
ylase inhibitor carbidopa, was used to prevent the conversion of L-
DOPA to DA before it entered the brain. Low doses of L-DOPA
were administered in an effort to avoid the potential confound of
side effects such as nausea, vomiting and dizziness. On the test
day, participants arrived in the laboratory at 11:30 AM and
completed baseline subjective state questionnaires and drug
screening. At 12:30 PM, participants ingested two green capsules
containing either placebo or one of the two doses of L-DOPA.
Participants completed the mood questionnaires at three addi-
tional times: 45 minutes, 105 minutes and 165 minutes post-
capsule ingestion. Cognitive testing commenced 45 minutes
following ingestion of the capsules, coinciding with the time to
peak blood concentration of L-DOPA and lasted until 3:30 PM.
Female participants who were not taking oral contraceptives were
tested within 10 days of the start of menstruation because previous
studies have shown that females are more sensitive to reward in the
follicular compared to the luteal phase of the menstrual cycle [87–
89].
Personality Measures
All subjects completed the Tridimensional Personality Ques-
tionnaire (TPQ) [90], Substance Use Risk Profile (SURPS) [91]
and the Neuroticism-Extroversion-Openness Five Factor Invento-
ry (NEO-FFI) [92]. Of specific interest in the present study were
the TPQ Novelty Seeking factor and two of its subscales (NS1,
Exploratory-Excitability and NS2, Impulsiveness), the SURPS
factors Impulsivity and Sensation Seeking, and the NEO-FFI
factor Extraversion. Each drug group was further sub-divided into
high and low groups based on a median split of these personality
factor scores for each subject.
Mood and Subjective Effects Measures
Subjective effects were measured with the bipolar Profile of
Mood States (POMS), a sensitive measure of small rapid changes
in mood [93,94], and a visual analog scale (VAS) labeled
‘‘Nauseous’’. The POMS is comprised of 72 adjectives that
describe various mood states. Participants indicate the extent to
which they feel these states at each time point on a scale ranging
from 0 (‘‘not at all’’) to 4 (‘‘extremely’’). The POMS items are
then converted into 6 empirically derived sub-scales: Elated-
Depressed, Composed-Anxious, Agreeable-Hostile, Confident-
Unsure, Energetic-Tired and Clearheaded-Confused. Both
questionnaires were administered at four times on the test day:
at baseline, and at 45, 105 and 165 minutes post-capsule
ingestion.
Data Analyses
Data analyses were conducted using SPSS Statistics (version
18.0; IBM, Chicago, Illinois). Each drug group was further
subdivided based on a median split of scores for the approach-
related personality traits of Impulsivity, Extraversion, Sensation
Seeking and Novelty Seeking, yielding high and low groups for
each factor. Three separate analyses were conducted for TPQ
Novelty Seeking: the total score as well as scores for the
Exploratory-Excitability (NS1) and Impulsiveness (NS2) subscales.
Three-way mixed design ANOVAs were used to assess the effects
of drug group (independent factor, 3 levels: placebo, 100 mg L-
DOPA, 200 mg L-DOPA) and personality trait sub-group
(independent factor, 2 levels: high and low) across time (repeated
factor, 4 levels: baseline, +45 minutes, +105 minutes and
+165 minutes) for all of the mood and subjective effects measures.
Two-way independent groups ANOVAs were used to assess the
effects of drug group and personality trait subgroup on POMS
absolute peak change scores, calculated as the largest difference
between any of the three time points and baseline. Post-hoc Least
Significant Differences (LSD) tests were used whenever an
ANOVA yielded a significant result. The significance for all
statistical tests was p,0.05.
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